Brian Stephenson Purchases 6,250 Shares of Sensei Biotherapeutics (NASDAQ:FTH) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson acquired 6,250 shares of the stock in a transaction dated Friday, June 26th. The shares were acquired at an average cost of $24.95 per share, with a total value of $155,937.50. Following the completion of the transaction, the chief financial officer owned 33,054 shares in the company, valued at approximately $824,697.30. This represents a 23.32% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Sensei Biotherapeutics Price Performance

FTH stock opened at $22.87 on Friday. The company has a market cap of $30.65 million, a P/E ratio of -0.16 and a beta of -0.25. Sensei Biotherapeutics, Inc. has a fifty-two week low of $6.32 and a fifty-two week high of $36.76.

Analyst Upgrades and Downgrades

FTH has been the topic of a number of recent analyst reports. HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a research report on Monday, June 22nd. They issued a “buy” rating and a $60.00 target price on the stock. Weiss Ratings assumed coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. Finally, Robert W. Baird assumed coverage on Sensei Biotherapeutics in a research note on Friday. They set an “outperform” rating and a $57.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Sensei Biotherapeutics currently has an average rating of “Buy” and a consensus price target of $58.50.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.